Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2017 | main topic | Ausgabe 9-10/2017

Wiener Medizinische Wochenschrift 9-10/2017

Orphan diseases: state of the drug discovery art

Wiener Medizinische Wochenschrift > Ausgabe 9-10/2017
PhD Claude-Henry Volmar, MD, PhD Claes Wahlestedt, PhD Shaun P. Brothers


Since 1983 more than 300 drugs have been developed and approved for orphan diseases. However, considering the development of novel diagnosis tools, the number of rare diseases vastly outpaces therapeutic discovery. Academic centers and nonprofit institutes are now at the forefront of rare disease R&D, partnering with pharmaceutical companies when academic researchers discover novel drugs or targets for specific diseases, thus reducing the failure risk and cost for pharmaceutical companies. Considerable progress has occurred in the art of orphan drug discovery, and a symbiotic relationship now exists between pharmaceutical industry, academia, and philanthropists that provides a useful framework for orphan disease therapeutic discovery. Here, the current state-of-the-art of drug discovery for orphan diseases is reviewed. Current technological approaches and challenges for drug discovery are considered, some of which can present somewhat unique challenges and opportunities in orphan diseases, including the potential for personalized medicine, gene therapy, and phenotypic screening.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 9-10/2017

Wiener Medizinische Wochenschrift 9-10/2017 Zur Ausgabe